stockrow
Friday 6 November 2026
Export SDGR’s income statement to Excel — free account
Schrodinger, Inc.
SDGR Healthcare Health Information Services
Schrodinger, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $255.9 million, up 23.3% from fiscal 2024.
- Revenue
- +18.7%
- EPS
- −11.1%
- Free cash flow
- +21.6%
Quarter to September 2026, against a year earlier
29.96
1.19
+4.14%
Follow SDGR
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.64 | 4.69 | 3.30 | 5.13 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 105.42 | |
P/Operating CF |
(48.86) | (35.64) | (56.66) | (81.60) | |
P/B ratio |
7.70 | 3.69 | 2.68 | 3.61 | |
Price to Tangible BV |
7.83 | 3.75 | 2.72 | 3.66 | |
EV/Sales |
7.25 | 3.07 | 1.70 | 3.56 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(17.33) | (6.27) | (2.99) | 65.53 | |
EV/FCF |
(16.71) | (6.10) | (2.93) | 73.12 | |
Quick Ratio |
2.25 | 2.65 | 2.68 | 2.68 | |
Current Ratio |
2.75 | 2.71 | 2.74 | 2.75 | |
Net Debt/EBITDA |
15.14 | 10.45 | 8.59 | 25.59 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.43 | 0.39 | 0.37 | 0.33 | |
Operating CF/Net income |
1.26 | (5.70) | 0.25 | (0.49) | |
Capex/Depreciation |
(0.88) | (0.24) | (1.70) | (0.03) | |
Research and Development Expense of Revenue |
52.86% | 69.62% | 74.80% | 47.46% | |
Selling, General and Administrative Expense of Revenue |
46.97% | 56.01% | 58.92% | 37.89% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
12.30% | 14.93% | 15.49% | 11.41% | |
Graham Net Nets |
0.06 | 0.13 | 0.17 | 0.12 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.54%) | (4.55%) | (12.41%) | (7.94%) | |
Free Cash Flow Yield |
(5.02%) | (10.73%) | (17.65%) | 0.95% | |
Revenue per Share |
0.86 | 0.79 | 0.79 | 1.19 | |
Operating CF per Share |
(0.64) | (0.46) | (0.20) | (0.22) | |
Capex per Share |
(0.02) | 0.00 | (0.03) | 0.00 | |
Free Cash Flow per Share |
(0.65) | (0.46) | (0.23) | (0.22) | |
Cash per Share |
4.99 | 5.61 | 5.49 | 5.48 | |
Shareholders Equity per Share |
4.03 | 4.40 | 4.24 | 4.96 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.03 | 4.40 | 4.24 | 4.96 | |
Free Cash Flow |
(48.87) | (34.43) | (17.34) | (16.13) | |
Working Capital |
290.25 | 296.63 | 294.42 | 330.13 | |
Capital Expenditures |
(1.29) | (0.36) | (2.51) | (0.04) | |
Net Current Asset Value |
146.43 | 159.04 | 143.32 | 157.16 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.04 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 38.95 | 47.25 | 179.86 | |
Average Payables |
8.58 | 9.56 | 11.90 | 11.06 | |
Average Assets |
632.80 | 664.32 | 688.61 | 774.69 | |
Average Common Equity |
311.59 | 335.91 | 343.53 | 392.75 |
Columns are period end dates · fundamentals updated 4 Nov 2026